Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures 2
NCT02284295 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 352
Last updated 2015-04-14
Summary
The objective of this study is to investigate molecular, cytological and genetic features of occupational chronic obstructive pulmonary disease (COPD) in conditions of different occupational exposures. In order to achieve this goal serum pro-inflammatory cytokines and standard inflammation markers level, hemostasis, cytological analysis of bronchoalveolar lavage fluid and association of single nucleotide polymorphisms (SNPs) rs1800470 transforming growing factor β1 (TGF β1) gene, rs1828591 hedgehog interacting protein (HHIP) gene, rs4129267 interleukin 6 receptor (IL-6R) gene, rs1051730 nicotinic acetylcholine receptor 3 (CHRNA3) gene with COPD in subjects exposed to silica dust and in those exposed to polycyclic aromatic hydrocarbons exhaust will be investigated. The relationship between genotype and phenotype characteristics, such as an inflammation activity, assessed by C-reactive protein (hsCRP) and tumor necrosis factor alpha (TNF α) serum concentration, in different occupational COPD groups will be studied. The hypothesis is that the mechanisms underlying disease development and progression are different due to environmental risk factor that reflex in differs in disease attributes - molecular biomarkers, cytology results and genetic susceptibility between COPD due to dust, COPD due to chemicals and COPD in smokers therefore COPD can be subdivided into ecological phenotypes according to environmental risk factor.
Conditions
Interventions
- OTHER
-
exposure to respirable silica dust
History of exposure to respirable silica dust due to job
- OTHER
-
exposure to aromatic hydrocarbons
history of exposure to aromatic hydrocarbons due to job
Sponsors & Collaborators
-
Siberian Branch of the Russian Academy of Medical Sciences
collaborator OTHER -
Novosibirsk City Hospital #2
lead OTHER
Principal Investigators
-
Liubov Shpagina, PhD · Novosibirsk City Hospital #2, Novosibirsk State Medical University
Eligibility
- Min Age
- 40 Years
- Max Age
- 75 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-11-30
- Primary Completion
- 2014-11-30
- Completion
- 2014-11-30
Countries
- Russia
Study Locations
More Related Trials
-
COPD Originates in Polluted Air
NCT02236039 ·Status: COMPLETED ·Phase: NA
-
Characterization of Aerosol Generation and Transport in the Human Lung of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
NCT01088633 ·Status: COMPLETED ·Phase: NA
-
A Translational Study for Prediction of Biomarkers and Identification of Phenotype and Endotype of COPD and Early COPD Outcomes in Chinese Population
NCT06724848 ·Status: RECRUITING
-
Chronic Obstructive Pulmonary Disease in Combination With Atherosclerosis (Clinical and Biochemical Study)
NCT04474717 ·Status: COMPLETED ·Phase: NA
-
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints
NCT00292552 ·Status: COMPLETED
-
Oxidative Damage and Antioxidant Mechanisms in COPD
NCT02406053 ·Status: COMPLETED
-
Changes in Cytokine Levels During an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT00281242 ·Status: COMPLETED
-
Airway Inflammation and Remodeling in Asthma and COPD.
NCT02069054 ·Status: COMPLETED
-
Air Pollution and Health of COPD Patients
NCT05076630 ·Status: COMPLETED
-
COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function
NCT01974154 ·Status: TERMINATED
-
Markers for Chronic Obstructive Pulmonary Disease (COPD)
NCT00180622 ·Status: WITHDRAWN
-
The Oxidative Stress, Inflammatory Markers, and Metabolomics Response to Exercise in Patients With COPD
NCT04117412 ·Status: COMPLETED ·Phase: NA
-
The Anti-oxidant Effects of N-Acetylcysteine in Chronic Obstructive Pulmonary Disease (COPD)
NCT03956888 ·Status: COMPLETED ·Phase: PHASE3
-
Role of Systemic Inflammation in Increase of Cardio-vascular Risk in Chronic Obstructive Pulmonary Disease
NCT02888886 ·Status: COMPLETED ·Phase: NA
-
Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis, Utilisation of Health Care Resources in Patients With COPD
NCT01245933 ·Status: COMPLETED
-
Is COPD a Risk Factor for Cardiovascular Disease?
NCT02162095 ·Status: COMPLETED
-
Biological Markers for Professional COPD
NCT03240198 ·Status: UNKNOWN
-
Biomarkers for Diagnosis and Treatment of COPD
NCT02633280 ·Status: COMPLETED
-
Study on the Etiology, Risk Factors and Pathogenesis of COPD Based on Clinical Bioinformatics
NCT05069194 ·Status: UNKNOWN
-
A Cohort of Patients With Chronic Pulmonary Disease
NCT04050943 ·Status: UNKNOWN
-
Clinical And Social Characteristics and Demographics in COPD
NCT02882165 ·Status: COMPLETED ·Phase: NA
-
Pulmonary Fibrosis and Telomerase Mutation Study
NCT01501578 ·Status: COMPLETED
-
Dyspnea in Patients With Pulmonary Fibrosis
NCT00611182 ·Status: COMPLETED
-
Clinical Features of Smoker Patients With Chronic Obstructive Pulmonary Disease
NCT04711629 ·Status: UNKNOWN ·Phase: NA
-
Predictive Value of Inflammatory Biomarkers and FEV1 for COPD
NCT03532893 ·Status: COMPLETED